

REMARKS/ARGUMENTS

Claims 1, 2, 6, 7 and 10-19 are pending in the captioned application and are finally rejected. Applicants hereby amend claim 1 and 6. Applicants also cancel claim 7. Applicants respectfully request reconsideration and allowance of the claims.

In the Advisory Action, the Examiner states that Applicants' disclosure does not "recite or define that [the] method is performed at high linear flow rate that disallow cells and cell fragments from readily migrating down to the sensing surface". Applicants respectfully disagree. In response, Applicants submit that the specification describes that laminar flow separates the free ligands from cells and ligands bound to cell surfaces (see lines 5-11 of paragraph 54 of the published US application). Thus, the method is properly described.

Applicants respectfully assert that the claims are in allowable form and earnestly solicit the allowance of claims 1, 2, 6 and 10-13.

Appl. No. 10/815,166
Amendment dated April 30, 2009
Reply to Office action of January 5, 2009

Early and favorable consideration is respectfully requested.

Respectfully submitted,

GE Healthcare Bio-Sciences Corp.

By: /Yonggang Ji/
Yonggang Ji
Reg. No.: 53,073
Agent for Applicants

GE Healthcare Bio-Sciences Corp.
800 Centennial Avenue
P. O. Box 1327
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875
Fax: (732) 457-8463

I hereby certify that this correspondence is being uploaded to the United States Patent and Trademark Office using the Electronic Filing System on April 30, 2009.

Signature: /Melissa Leck/

Name: Melissa Leck